|
gptkb:Aplidin
|
phase III
|
|
gptkb:БИЧ-46
|
investigational
|
|
gptkb:roscovitine
|
Phase II
|
|
gptkb:COVID-19_vaccine_development_(Moderna)
|
Phase 2
|
|
gptkb:IMR-687
|
Phase 2
|
|
gptkb:adult_hemoglobin
|
hemoglobin electrophoresis
|
|
gptkb:STK11_gene
|
available
|
|
gptkb:Abrysvo
|
Phase 3
|
|
gptkb:Toripalimab
|
gptkb:NCT02915432
|
|
gptkb:camrelizumab
|
Phase III
|
|
gptkb:Single_dose_(Johnson_&_Johnson)
|
gptkb:ENSEMBLE_trial
|
|
gptkb:NCT05240898
|
Phase 3
|
|
gptkb:KIT_gene
|
KIT mutation analysis
|
|
gptkb:Aravive
|
Phase 3 trial for batiraxcept in ovarian cancer
|
|
gptkb:Firehawk_stent
|
TARGET All Comers
|
|
gptkb:PI3K-gamma_inhibitor_IPI-549
|
advanced cancers
|
|
gptkb:N-219
|
Phase 1/2
|
|
gptkb:IDUA_gene
|
sequencing
|
|
gptkb:APOB
|
APOB blood test
|
|
gptkb:ImmTOR_immune_tolerance_platform
|
in clinical development
|